MedTrace Logo

HIV Indicator Diseases Across Europe Study

NCT01681706 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 14000

Last updated 2012-09-10

No results posted yet for this study

Summary

The purpose of this non-interventional study is to implement a survey initiative to assess HIV prevalence for one or more diseases and/or conditions within a specific segment of the population not yet diagnosed with HIV, who presents for care with the specific disease/condition.

The list of diseases below is not indicative of the most important indicator diseases for HIV but rather a list of diseases suggested for surveillance.

This study will enrol patients presenting with the following diseases/conditions:

1. Presenting for care of malignant lymphoma, irrespective of type
2. Presenting for care of cervical or anal dysplasia or cancer, (Cervical CIN II and above)
3. Presenting for care of Hepatitis B or C virus infection (acute or chronic - and irrespective of time of diagnosis relative to time of survey),
4. Presenting with ongoing mononucleosis-like illness
5. Presenting with unexplained leukocytopenia or thrombocytopenia lasting at least 4 weeks
6. Presenting with seborrheic dermatitis / exanthema
7. Presenting with pneumonia, admitted to hospital for at least 24h
8. Presenting with unexplained lymphadenopathy
9. Presenting with peripheral neuropathy of unknown cause (diagnosed by neurologist)
10. Presenting with primary lung cancer
11. Presenting with severe or recalcitrant psoriasis (newly diagnosed)

Conditions

Sponsors & Collaborators

  • Jesper Grarup

    lead OTHER

Principal Investigators

  • Jens D Lundgren, Prof. · University of Copenhagen

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-02-29
Primary Completion
2013-12-31
Completion
2014-06-30

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01681706 on ClinicalTrials.gov